On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback